TORNTPHARM Torrent Pharmaceuticals Q2 FY25 results (Jul–Sep 2024) and concall
Management summary
- Torrent Pharma delivered a robust Q2 FY25 performance led by its branded businesses in India and Brazil.
- Despite a temporary disruption in insulin manufacturing and currency headwinds in Brazil, the company maintained strong operating leverage and EBITDA growth.
- Management remains focused on chronic therapy outperformance in India and deleveraging, aiming to become net cash positive by FY26.
Source: Inve concall analysis and management guidance record.
Guidance & targets
2Margin
EBITDA Margin Improvement Margin · annually for next 3 years · Medium confidence 50-100 bps
Debt
Debt Repayment Debt · H2 FY25 · High confidence ₹500-600 crores
Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.
Q&A highlights
2Insulin revenue shortfall and recovery Direct
Shortfall is planned to be significantly recovered in quarter four of this year and consequently there will not be any impact on a full year basis.
Clarifies that the ₹40 crore revenue miss in Q2 is a timing issue due to maintenance, not a structural loss.
Asked by Tushar Manudhane
US business growth trajectory Direct
I don't expect the US to ramp up anywhere very fast in the next 2 years. So, it'd be a slow ramp up, unless we get lucky with one or the other opportunities.
Sets realistic expectations for the US market, noting that most filed ANDAs are old and approvals will be gradual.
Asked by Damayanti Kerai
Unlock risks & concerns, Q3 FY25 watchlist, and full call analysis
You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:
- 3 risks, concerns & management red flags
- Watchlist triggers for Q3 FY25
- +4 more guidance targets & verbatim management quotes
- +1 more analyst Q&A exchange & evasion checks
- Full section-by-section call narrative
Sign in to use your monthly call allowance.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image





